Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years

Next Previous
Trial Profile

A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OVX-836 (Primary) ; OVX-836 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man
  • Sponsors OSIVAX

Most Recent Events

  • 15 Oct 2021 Results reporting first clinical safety and immunogenicity data obtained in healthy volunteers administered with OVX836 by IM route published in the Journal of Infectious Diseases
  • 18 Sep 2019 Status changed from active, no longer recruiting to completed.
  • 10 Jul 2019 According to an OSIVAX media release, initial results are expected in the second half of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top